Skip to main content

Table 1 Patient Demographics and Baseline Characteristics

From: Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Characteristics

(N = 50)

Age, median (range), years

50.0 (21–71)

  < 65 years, n (%)

46 (92.0)

  ≥ 65 years, n (%)

4 (8.0)

Sex, n (%)

 Male

24 (48.0)

 Female

26 (52.0)

Geographic region, n (%)

 USA

27 (54.0)

 Europe

22 (44.0)

 Asia

1 (2.0)

ECOG PS, n (%)

 0

19 (38.0)

 1

31 (62.0)

Median time since first diagnosis (range), years

1.6 (0.2–15.1)

Median time since last disease progression (range), months

0.92 (0.33–8.61)

Number of prior lines of systemic anticancer therapy, n (%)

 1

13 (26.0)

 2

18 (36.0)

 3

10 (20.0)

  ≥ 4

9 (18.0)

Receiving concomitant mitotane, n (%)

25 (50.0)

PD-L1 expression on tumor cells (≥1% cutoff), n (%)

 Negative

27 (54.0)

 Positive

15 (30.0)

 Not evaluable

8 (16.0)

PD-L1 expression on tumor cells (≥5% cutoff), n (%)

 Negative

30 (60.0)

 Positive

12 (24.0)

 Not evaluable

8 (16.0)